Company / Shareholders' Equity
Bristol Myers Squibb Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$18.5B
FY2025
5-year range
$16.3B / $35.9B
FY2021-FY2025
Trend
+13.1%
vs FY2024
Sector context
#8 of 213
Health Care
What the data says
Among 213 Health Care companies, Bristol Myers Squibb is in the top 4% for shareholders' equity. Shareholders' Equity returned to growth in FY2025 after 5 years of decline, reaching $18.5B.
Based on SEC 10-K filings.
$18.5B in FY2025 with a 5-year CAGR of -13.4%. Top quartile in the Health Care sector.
Declined from $29.4B to $18.5B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -15.9%
- 5-Year CAGR
- -13.4%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 213This company $18.5B Sector average $2.5B
▼
+624.7% above sector average
Key checks
Key Insights
- 5-year CAGR of -13.4%, indicating a declining trend.
- In FY2025, shareholders' equity increased 13.1% year-over-year.
- Ranks #8 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2019.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.5B | +13.1% |
| FY2024 | $16.3B | -44.5% |
| FY2023 | $29.4B | -5.3% |
| FY2022 | $31.1B | -13.6% |
| FY2021 | $35.9B | -5.0% |
| FY2020 | $37.8B | -26.7% |
| FY2019 | $51.6B | +267.7% |
| FY2018 | $14.0B | +19.5% |
| FY2017 | $11.7B | -27.4% |
| FY2016 | $16.2B | +13.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026